GWM
INDV icon

Gilpin Wealth Management’s Indivior Pharmaceuticals INDV Stock Holding History

Gilpin Wealth Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$108 Sell
3
-8
-73% -$302 ﹤0.01% 1282
2026
Q2 		$452 Buy
11
+9
+450% +$326 ﹤0.01% 711
2026
Q1 		$61 Sell
2
-6
-75% -$198 ﹤0.01% 978
2025
Q4 		$288 Buy
+8
New +$244 ﹤0.01% 557

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Gilpin Wealth Management's INDV Position: Q3 2026 in Review

Gilpin Wealth Management reduced its Indivior Pharmaceuticals (INDV) stake by 73% in Q3 2026, selling an estimated $302 and leaving 3 shares worth $108. The position accounts for ﹤0.01% of the portfolio, ranked #1282.

Gilpin Wealth Management first reported a position in INDV in Q4 2025 and has held it in 4 quarters since. The position peaked at $452 in Q2 2026. 8 funds tracked by Wall St. Rank hold INDV as of Q3 2026.

  • Gilpin Wealth Management held 3 shares of Indivior Pharmaceuticals worth $108 as of Q3 2026.
  • Gilpin Wealth Management sold 8 Indivior Pharmaceuticals shares in Q3 2026, an estimated $302.
  • Indivior Pharmaceuticals made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q3 2026, its #1282 holding.
  • Gilpin Wealth Management first reported a position in Indivior Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Gilpin Wealth Management's Indivior Pharmaceuticals position peaked at $452 in Q2 2026.
  • 8 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.